Skip to main
TNGX
TNGX logo

Tango Therapeutics (TNGX) Stock Forecast & Price Target

Tango Therapeutics (TNGX) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tango Therapeutics Inc. is focused on developing innovative precision oncology therapies, particularly with its two MTA-cooperative PRMT5 inhibitors, TNG462 for non-CNS cancers and TNG456 for CNS cancers, which positions the company favorably within the biotech sector. With a market capitalization of approximately $400 million and about $300 million in cash, the company is well-capitalized to support the next stages of development for TNG462, which could significantly enhance its stock value if it generates compelling data. Additionally, the promising early results from their therapeutic combinations and the ongoing progression of TNG456 highlight the potential for deeper and more frequent regressions in target cancer models, supporting a positive outlook for the company’s future performance.

Bears say

Tango Therapeutics Inc faces significant risks that could adversely impact its stock performance and market competitiveness, primarily stemming from its lead assets, TNG908 and TNG462, which may yield negative clinical results or experience delays in their advancement into registrational programs. Furthermore, the company contends with heightened competitive pressures from other clinical-stage PRMT5 inhibitors and a potential inability to secure timely regulatory approvals, which could hinder its commercialization efforts. Lastly, the noted long-term dilution risk and the lackluster stock recovery following recent adverse news contribute to a negative overall outlook for the company's financial stability and growth potential.

Tango Therapeutics (TNGX) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tango Therapeutics (TNGX) Forecast

Analysts have given Tango Therapeutics (TNGX) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Tango Therapeutics (TNGX) has a Strong Buy consensus rating as of Jul 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tango Therapeutics (TNGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.